|Bellerophon Therapeutics Inc., of Warren, N.J.||Inopulse||Pulsatile nitric oxide delivery system||Pulmonary hypertension associated with pulmonary fibrosis||Finalized, in consultation with FDA, key elements of planned pivotal phase III trial, including use of moderate to vigorous physical activity as the primary endpoint for approval, the population of PF subjects at risk of PH, as well as the dose of iNO45 (45 mcg/kg IBW/hr)|
|Cadent Therapeutics Inc., of Cambridge, Mass.||CAD-9303||Positive allosteric modulator of NMDA||Schizophrenia||FDA cleared the IND for a phase I trial in schizophrenia patients and healthy volunteers|
|Daré Biosciences Inc., of San Diego||DARE-BV1||Thermosetting bioadhesive hydrogel containing clindamycin phosphate 2%||Bacterial vaginosis||FDA granted fast track designation|
|Freeline Therapeutics Ltd., of London||FLT-190||Liver-directed AAV gene therapy||Fabry disease||European Commission granted orphan designation|
For more information about individual companies and/or products, see Cortellis.